

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,  
Debtors


Case No.: 19-23649 (RDD)  
Reporting Period December 1, 2019 to December 31, 2019

CORPORATE MONTHLY OPERATING REPORT


REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

  
\_\_\_\_\_  
Signature of Authorized Individual\*

\_\_\_\_\_  
Date 2/3/2020

  
\_\_\_\_\_  
Printed Name of Authorized Individual

\_\_\_\_\_  
Date 2/3/2020

\*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period December 1, 2019 to December 31, 2019

**SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)**

Case No.	Debtor Entity Name:	Net Receipts <sup>2</sup>	Net Disbursements <sup>1</sup>
19-23648	PURDUE PHARMA INC.	15	\$ 220,279
19-23649	PURDUE PHARMA L.P.	122,590,093	\$ 168,596,568
19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	\$ -
19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	\$ 281,594
19-23652	PURDUE PHARMACEUTICALS L.P.	-	\$ 3,903,610
19-23653	IMBRIUM THERAPEUTICS L.P.	-	\$ 1,870,806
19-23654	ADLON THERAPEUTICS L.P.	-	\$ 8,174,202
19-23655	GREENFIELD BIO VENTURES L.P.	-	\$ 362,721
19-23656	SEVEN SEAS HILL CORP.	-	\$ -
19-23657	OPHIR GREEN CORP.	-	\$ -
19-23658	PURDUE PHARMA OF PUERTO RICO	-	\$ 10,793
19-23659	AVRIO HEALTH L.P.	1,694	\$ 5,536,695
19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	\$ 6,894
19-23661	PURDUE NEUROSCIENCE COMPANY	-	\$ -
19-23662	NAYATT COVE LIFESCIENCE INC.	-	\$ 1,422,684
19-23663	BUTTON LAND L.P.	-	\$ -
19-23664	PAUL LAND INC.	-	\$ -
19-23665	QUIDNICK LAND L.P.	-	\$ -
19-23666	RHODES ASSOCIATES L.P.	-	\$ -
19-23667	RHODES PHARMACEUTICALS L.P.	20,589,083	\$ 9,669,975
19-23668	RHODES TECHNOLOGIES	435,590	\$ 6,571,048
19-23669	UDF LP	-	\$ -
19-23670	SVC PHARMA LP	-	\$ 494,270
19-23671	SVC PHARMA INC.	-	\$ -
<b>Totals:</b>		<b>\$ 143,616,475</b>	<b>\$ 207,122,140</b>

**Footnotes**

1) The Net Disbursements exclude intercompany transactions among Debtors

2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
December 31, 2019

**BANK ACCOUNT BALANCES (\$)**

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	750,000
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,813,909
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,007,843
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	3,502,717
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,661,342
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Account	201,044,731
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Account	100,268,362
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx8720	Account	100,072,025
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	99,586,933
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	599,191,973
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	16,317,409
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	255,817
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,222,918
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	58,889,981
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,010,021
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	125,293,418
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,342,662
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx4018	Trust	25,043,980
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	743,697
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	125,308
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
December 31, 2019

**BANK ACCOUNT BALANCES (\$)**

<b>Debtor</b>	<b>Bank</b>	<b>Account Number</b>	<b>Description</b>	<b>Balance as of Month End</b>
Rhodes Technologies	JP Morgan Chase	xxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
<b>Total</b>				<b>1,386,495,707</b>

---

In re: **PURDUE PHARMA L.P., et al.,  
Debtors**

Case No.: 19-23649 (RDD)  
December 31, 2019

**CONSOLIDATED STATEMENT OF OPERATIONS (\$M)** <sup>1,2</sup>  
**Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.**

	Current Month	Cumulative Filing to Date <sup>3</sup>
Net Sales	\$70	\$311
Cost of Goods Sold	(28)	(100)
Gross Profit	41	210
Sales and Promotion	(7)	(38)
Research and Development	(13)	(34)
General and Administrative	(16)	(40)
Legal Fees - Ordinary Course	(1)	(3)
Medical Affairs	(3)	(11)
Milestones & Alliances	-	(1)
Health Care Reform Fee	(2)	(4)
Other US	-	(1)
Incentive Bonus	(8)	(16)
Total Operating Expenses	(50)	(148)
Operating Profit	(9)	63
Legal Fees - Non-Recurring	(26)	(97)
Other	(13)	(7)
Total Non-Operating Expenses	(39)	(104)
Profit	(\$49)	(\$41)

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
December 31, 2019

**PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000)** <sup>1,2</sup>

	<b>Current Month</b>	<b>Cumulative Filing to Date</b> <sup>3</sup>
Management Fee Income	\$29	\$115
General and Administrative Expenses	(14)	(29)
Operating Income	15	86
Other income:	-	-
Income from Unconsolidated Associated Companies	(276)	(136)
Interest income - associated companies	-	-
Total Other Income	(276)	(136)
Pre-Tax Income	(261)	(50)
Income Tax Provision	26	(32)
Net Income	(\$236)	(\$83)

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
December 31, 2019

CONSOLIDATED BALANCE SHEET (\$M) <sup>1,2</sup>	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
<b>ASSETS</b>	
<b>CURRENT ASSETS</b>	
Cash & Cash Equivalents	\$1,116
Available For Sale Investments	1
Accounts Receivable, Net	64
Due From Associated Companies	13
Other Receivables	3
Inventories, Net	88
Prepaid Expenses & Other Current Assets	64
Restricted Cash	13
<b>TOTAL CURRENT ASSETS</b>	<b>1,362</b>
Property and Equipment, net	142
Investments at Cost	28
Restricted Cash - Long-Term	256
Intangible Assets, Net	103
Other Assets	17
<b>TOTAL ASSETS</b>	<b>\$1,908</b>
<b>LIABILITIES AND EQUITY</b>	
<b>CURRENT LIABILITIES</b>	
Accounts Payable	\$55
Accrued Expenses	342
Due to Associated Companies	1
<b>TOTAL CURRENT LIABILITIES</b>	<b>398</b>
Other Liabilities	108
Due to Associated Companies	11
Liabilities Subject to Compromise <sup>3</sup>	3,017
<b>TOTAL LIABILITIES</b>	<b>3,534</b>
<b>EQUITY</b>	
Retained Earnings & Partners' Capital	(1,580)
Accumulated Other Comprehensive Loss	(46)
<b>TOTAL EQUITY</b>	<b>(1,626)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$1,908</b>

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
December 31, 2019

**PURDUE PHARMA, INC. BALANCE SHEET (\$000) <sup>1,2</sup>**

	Book Value
<b>Assets</b>	
Currents assets:	
Cash and cash equivalents	\$744
Prepaid expenses	90
Due from Associated Companies	774
<b>Total current assets</b>	<b>1,608</b>
Investments	8,818
Deferred income taxes	147
<b>Total assets</b>	<b>\$10,573</b>
<b>Liabilities and equity</b>	
Current liabilities:	
Accounts payable	\$845
Due to Associated Companies	401
Accrued Expenses	23
<b>Total liabilities</b>	<b>1,269</b>
Common stock	1
Additional paid-in capital	499
Retained earnings	8,869
Accumulated other comprehensive loss	(65)
<b>Total equity</b>	<b>9,304</b>
<b>Total liabilities and equity</b>	<b>\$10,573</b>

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.



In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period December 1, 2019 to December 31, 2019

**SCHEDULE OF POST PETITION TAXES**

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



---

Signature

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period December 1, 2019 to December 31, 2019

**SCHEDULE OF PAYMENTS TO INSIDERS (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Compensation</b>		
Chomiak, Caroline	26,324	104,905
Kesselman, Marc L <sup>2</sup>	158,750	555,625
Landau, Craig J	216,418	775,711
Lowne, Jonathan R	74,066	273,347
Lundie, David R	64,920	227,220
Mancinelli II, Vincent F	39,947	139,632
Mazzi, Christian	46,153	189,030
Medeiros, Paul	49,646	173,761
Shamblen, Randy	39,073	136,643
Strassburger, Philip C	69,355	242,741
<b>Total Compensation</b>	<b>784,652</b>	<b>2,818,615</b>
<b>Director Fees</b>		
Boer, F Peter	-	175,000
Buckfire, Kenneth A	-	175,000
Cola, Michael	-	175,000
Collins, Michael J	-	25,000
Dubel, John	-	175,000
Miller, Robert S	208,333	416,667
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	-	175,000
<b>Total Director Fees</b>	<b>208,333</b>	<b>1,341,667</b>
<b>T&amp;E Reimbursements</b>		
Boer, F Peter	4,281	8,163
Buckfire, Kenneth A	1,028	1,179
Chomiak, Caroline	2,709	20,834
Debone, Louis	-	1,245
Dubel, John	1,757	3,747
Kesselman, Marc L	4,936	31,783
Landau, Craig J	9,660	30,539
Lowne, Jonathan R	46	602
Lundie, David R	4,709	18,435
Mancinelli II, Vincent F	2,864	23,215
Mazzi, Christian	948	3,645
Medeiros, Paul	6,313	19,352
Miller, Robert S	1,264	3,580
Pickett, Cecil	1,298	1,298
Shamblen, Randy	367	8,790
Strassburger, Philip C	681	7,629
<b>Total T&amp;E Reimbursements</b>	<b>42,861</b>	<b>184,037</b>
<b>Housing Payments</b>		
Kesselman, Marc L <sup>3</sup>	9,233	18,465
<b>Total Housing Payments</b>	<b>9,233</b>	<b>18,465</b>
<b>Indemnification Payments <sup>4</sup></b>		
Butcher, James A	-	527
Friedman, Michael	-	25,424
Landau, Craig J	-	1,486
Timney, Mark	989	989
<b>Total Indemnification Payments</b>	<b>989</b>	<b>28,427</b>
<b>Payments to Independent Associated Companies</b>		

Mundibiopharma Ltd	55,332	55,332
Mundipharma IT Services LTD	2,007	2,007
Mundipharma Laboratories GmbH	-	133,099
One Stamford Realty L.P.	1,727,680	2,480,270
Purdue Pharma Canada <sup>5</sup>	817,963	1,121,431
TXP Services Inc. <sup>6</sup>	630,368	1,757,064
<b>Total Payments to Independent Associated Companies</b>	<b>3,233,349</b>	<b>5,549,202</b>
<b>Total Payments to Insiders</b>	<b>4,279,417</b>	<b>9,940,413</b>

#### Footnotes

- 1) Represents payments made since the Commencement Date
- 2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.
- 3) Cumulative housing payments on behalf of Marc Kesselman have been revised to correct for an expense tracking error made by a third party vendor. Cumulative effect of the correction since the Commencement Date is \$4,363. Additionally, December totals represent two rent payments made (no payment was made in November).
- 4) In November, the Debtors paid \$2,513.11 to a non-attorney, legal services vendor. The Debtors later determined that these services were related to indemnified legal matters for Stuart Baker, a former officer of Purdue. Payment for indemnified legal services associated with Mr. Baker has not been authorized by the Special Committee of the Purdue Pharma Inc. Board of Directors. As such, the Debtors are seeking reimbursement of this payment and have not included it in the amounts above.
- 5) Payments to Purdue Canada include \$15,734.91 for Craig Landau's tax preparation services.
- 6) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period December 1, 2019 to December 31, 2019

**SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)**

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b><i>Estate Professionals</i></b>		
Davis Polk & Wardwell LLP	12,096,909	12,096,909
AlixPartners, LLP	696,859	696,859
PJT Partners LP	-	-
Prime Clerk LLC	907,432	1,921,577
<b>Total Estate Professionals</b>	<b>13,701,199</b>	<b>14,715,344</b>
<b><i>Creditor Committee Professionals</i></b>		
Akin Gump Strauss Hauer & Feld LLP	-	-
Bayard, P.A.	-	-
Jefferies LLC	-	-
Province, Inc.	-	-
Kurtzman Carson Consultants LLC	-	-
<b>Total Creditor Committee Professionals</b>	<b>-</b>	<b>-</b>
<b><i>Ad Hoc Committee Professionals</i></b>		
Kramer Levin Naftalis & Frankel LLP	909,740	909,740
Brown Rudnick LLP	-	-
Gilbert LLP	355,480	355,480
Otterbourg PC	275,740	275,740
FTI Consulting, Inc	623,714	623,714
Compass Lexecon	-	-
Coulter & Justice	-	-
<b>Total Ad Hoc Committee Professionals</b>	<b>2,164,673</b>	<b>2,164,673</b>
<b><i>Special Counsel to the Debtors</i></b>		
Dechert LLP	-	-
King & Spalding LLP	2,142,346	2,142,346
Skadden, Arps, Slate, Meagher & Flom LLP	1,427,890	1,427,890
Wilmer Cutler Pickering Hale and Door LLP	-	-
<b>Total Special Counsel Professionals</b>	<b>3,570,236</b>	<b>3,570,236</b>
<b>Ernst &amp; Young (Canada), Court Appointed Information Officer</b>	<b>-</b>	<b>-</b>
<b>Total Retained Restructuring Professional Fees</b>	<b>19,436,109</b>	<b>20,450,253</b>

**Footnotes**

1) Represents payments made since the Commencement Date

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period December 1, 2019 to December 31, 2019

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?	X		Payments have been made pursuant to the First Day Order authorizing the Debtors to pay certain prepetition taxes
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	